Macugen

RSS

Withdrawn

This medicine's authorisation has been withdrawn

pegaptanib
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 17 December 2018, the European Commission withdrew the marketing authorisation for Macugen (pegaptanib sodium) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, PharmaSwiss Ceska Republika s.r.o, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. 

Macugen was granted marketing authorisation in the EU on 31 January 2006 for the treatment of neovascular (wet) macular degeneration (AMD). 

The marketing authorisation was initially valid for a 5- year period. It was renewed for an additional 5-year period in 2010 and granted unlimited validity in 2015. The product had not been marketed in the EU since 1 January 2019. 

The European Public Assessment Report (EPAR) for Macugen is updated to indicate that the marketing authorisation is no longer valid.

български (BG) (663.47 kB - PDF)

Bekijk

español (ES) (596.59 kB - PDF)

Bekijk

čeština (CS) (637.04 kB - PDF)

Bekijk

dansk (DA) (596.95 kB - PDF)

Bekijk

Deutsch (DE) (597.88 kB - PDF)

Bekijk

eesti (ET) (596.17 kB - PDF)

Bekijk

ελληνικά (EL) (682.05 kB - PDF)

Bekijk

français (FR) (599.24 kB - PDF)

Bekijk

italiano (IT) (649.91 kB - PDF)

Bekijk

latviešu (LV) (648.04 kB - PDF)

Bekijk

lietuvių (LT) (602.49 kB - PDF)

Bekijk

magyar (HU) (636.13 kB - PDF)

Bekijk

Malti (MT) (647.6 kB - PDF)

Bekijk

Nederlands (NL) (595.16 kB - PDF)

Bekijk

polski (PL) (635.92 kB - PDF)

Bekijk

português (PT) (597.31 kB - PDF)

Bekijk

română (RO) (602.5 kB - PDF)

Bekijk

slovenčina (SK) (590.75 kB - PDF)

Bekijk

slovenščina (SL) (620.21 kB - PDF)

Bekijk

suomi (FI) (583.77 kB - PDF)

Bekijk

svenska (SV) (595.25 kB - PDF)

Bekijk

Product information

български (BG) (1.47 MB - PDF)

Bekijk

español (ES) (801.14 kB - PDF)

Bekijk

čeština (CS) (1.25 MB - PDF)

Bekijk

dansk (DA) (793.88 kB - PDF)

Bekijk

Deutsch (DE) (790.46 kB - PDF)

Bekijk

eesti (ET) (767.96 kB - PDF)

Bekijk

ελληνικά (EL) (1.61 MB - PDF)

Bekijk

français (FR) (793.99 kB - PDF)

Bekijk

hrvatski (HR) (826.96 kB - PDF)

Bekijk

italiano (IT) (772.63 kB - PDF)

Bekijk

latviešu (LV) (1.4 MB - PDF)

Bekijk

lietuvių (LT) (976.35 kB - PDF)

Bekijk

magyar (HU) (1.23 MB - PDF)

Bekijk

Malti (MT) (1.42 MB - PDF)

Bekijk

Nederlands (NL) (872.52 kB - PDF)

Bekijk

polski (PL) (1.35 MB - PDF)

Bekijk

português (PT) (765.25 kB - PDF)

Bekijk

română (RO) (1000.2 kB - PDF)

Bekijk

slovenčina (SK) (1.24 MB - PDF)

Bekijk

slovenščina (SL) (1.39 MB - PDF)

Bekijk

suomi (FI) (821.74 kB - PDF)

Bekijk

svenska (SV) (774.71 kB - PDF)

Bekijk

Íslenska (IS) (779.73 kB - PDF)

Bekijk

norsk (NO) (793.02 kB - PDF)

Bekijk
Latest procedure affecting product information:IB/0065
20/07/2016
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (538.8 kB - PDF)

Bekijk

español (ES) (458.33 kB - PDF)

Bekijk

čeština (CS) (540.02 kB - PDF)

Bekijk

dansk (DA) (460.05 kB - PDF)

Bekijk

Deutsch (DE) (458.67 kB - PDF)

Bekijk

eesti (ET) (460.41 kB - PDF)

Bekijk

ελληνικά (EL) (519.4 kB - PDF)

Bekijk

français (FR) (458.25 kB - PDF)

Bekijk

italiano (IT) (458.12 kB - PDF)

Bekijk

latviešu (LV) (539.76 kB - PDF)

Bekijk

lietuvių (LT) (533.6 kB - PDF)

Bekijk

magyar (HU) (536.46 kB - PDF)

Bekijk

Malti (MT) (537.49 kB - PDF)

Bekijk

Nederlands (NL) (457.9 kB - PDF)

Bekijk

polski (PL) (541.48 kB - PDF)

Bekijk

português (PT) (458.34 kB - PDF)

Bekijk

română (RO) (523 kB - PDF)

Bekijk

slovenčina (SK) (535.63 kB - PDF)

Bekijk

slovenščina (SL) (461.58 kB - PDF)

Bekijk

suomi (FI) (459.56 kB - PDF)

Bekijk

svenska (SV) (458.3 kB - PDF)

Bekijk

български (BG) (579.31 kB - PDF)

Bekijk

español (ES) (477.76 kB - PDF)

Bekijk

čeština (CS) (568.25 kB - PDF)

Bekijk

dansk (DA) (476.73 kB - PDF)

Bekijk

Deutsch (DE) (478.44 kB - PDF)

Bekijk

eesti (ET) (473.23 kB - PDF)

Bekijk

ελληνικά (EL) (571.1 kB - PDF)

Bekijk

français (FR) (484.43 kB - PDF)

Bekijk

italiano (IT) (476.75 kB - PDF)

Bekijk

latviešu (LV) (576.29 kB - PDF)

Bekijk

lietuvių (LT) (543.73 kB - PDF)

Bekijk

magyar (HU) (533.53 kB - PDF)

Bekijk

Malti (MT) (1.03 MB - PDF)

Bekijk

Nederlands (NL) (477.91 kB - PDF)

Bekijk

polski (PL) (573.21 kB - PDF)

Bekijk

português (PT) (477.16 kB - PDF)

Bekijk

română (RO) (546.55 kB - PDF)

Bekijk

slovenčina (SK) (569.93 kB - PDF)

Bekijk

slovenščina (SL) (561.68 kB - PDF)

Bekijk

suomi (FI) (476.99 kB - PDF)

Bekijk

svenska (SV) (477.99 kB - PDF)

Bekijk

Product details

Name of medicine
Macugen
Active substance
pegaptanib
International non-proprietary name (INN) or common name
pegaptanib
Therapeutic area (MeSH)
Wet Macular Degeneration
Anatomical therapeutic chemical (ATC) code
S01LA03

Pharmacotherapeutic group

Ophthalmologicals

Therapeutic indication

Macugen is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD).

Authorisation details

EMA product number
EMEA/H/C/000620
Marketing authorisation holder
PharmaSwiss Ceska Republika s.r.o

Jankovcova 1569/2c
Lighthouse
17000 Prague 7
Czech Republic

Marketing authorisation issued
31/01/2006
Revision
15

Assessment history

This page was last updated on

Share this page